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Problem Identification and Description of 
Need 
 Age-related macular degeneration (AMD) is the leading cause of severe, irreversible 
vision loss in the developed world1
 Low vision is socially isolating, decreases functioning and quality of life.  It is 
associated with significant comorbidities including falls and depression15
 In 2004, 1.75M Americans have severe AMD in at least one eye, and another 7.3M 
with high-risk features.  This number is estimated to increase to 3 million by 20201
 Risk Factors: Age,3 Caucasian race,2 smoking,5 genetic factors, family history6
 Prevalence increases with age, from 4.2% in persons age 43-54 to 46% in persons age 
75 or older3
 In Maine, 95% white, 38.7% age 50 and older4
 In Penobscot County, 16.5% age 65 and older.  This percentage is increasing4
 The Age-related Eye Disease Studies (AREDS) estimated that of the 8 million 
individuals considered high risk for the development of advanced stage AMD in 2003, 
300 thousand would have avoided progression to advanced stage disease and any 
subsequent vision loss (over a period of 5 years) had they received preventative 
AREDS nutritional supplementation8
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Problem Identification and Description of 
Need
 USPSTF currently has insufficient information to recommend routine 
screening for AMD based on visual acuity alone (Grade I 
recommendation)
 AAO Preferred Practice Patterns recommends yearly fundus exams 
and patient self monocular visual acuity and Amsler grid exams in 
individuals with early stage disease or positive family history13
 The AREDS and AREDS2 trials demonstrated a 10% - 30% reduction 
in progression to advanced disease in individuals with intermediate 
AMD (one or more drusen >125µm) supplemented with 
antioxidants and carotenoids11, 12
 Fundus examination is non-invasive and represents minimal risk to 
the patient
 Taken together, targeted questions, cursory fundus exam and 
Amsler grid testing now meets the criteria for a good screening test
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Public health costs
 Cost to Patient                                              
 $2,700/QALY* for monthly 
Bevacizumab9
 $63,000/QALY for monthly 
Ranibizumab9
 $14,000/QALY for implantable 
miniature telescope10
 Compare to $60 - $120 for AREDS 
nutritional supplements (1 year 
supply)
*Quality adjusted life-year
 Cost to Medical System
 $574 million in direct medical costs 
in 20047
 Wholesale prices of anti-VEGF 
intravitreal injections $50-$1950 per 
dose9
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Community perspective and 
support for project
“AMD is a disease with insidious onset and can be 
unilateral… so patients may not notice a change 
in vision until the disease is in the more advanced 
stages.  The most important things [PCPs] can do is 
identify and assess patients with risk factors, and 
make timely referrals.” 
- M.J., M.D., local ophthalmolgist*
“I live half an hour from the clinic.  I’ve never 
needed glasses so I have no reason to see an eye 
doctor. I only see the [PCP] when I’m sick.  A 
couple of my friends have AMD that were caught 
when it was already bad, and the thought of 
going blind is real scary.”
- Margaret Gauthier, Center for Family Medicine 
patient
4
“Not everyone receives routine eye exams 
because [vision insurance] is often not covered by 
employers.  Most of us ask about vision changes as 
part of the review of systems, but I don’t think 
specific screening questions and fundus exams are 
a big enough part of what we’re doing.  It would 
be interesting to gauge residents’ exposure to and 
proficiency with the fundus exam.” 
- Jessica Bloom-Foster, M.D., Center for Family 
Medicine Preceptor
*Interviewee consented to interview but declined publication of identifying information.  Names are on file in 
the University of Vermont College of Medicine Family Medicine Department
Intervention and methodology
 Patient                                              
 Assess patient knowledge of AMD risk factors, 
early signs and symptoms, and care 
management using a 14 point questionnaire 
 Questionnaire distributed at check-in by front 
office staff to all adult (18+) patients at CFM
 Education with a brief, informative, looping 
slideshow in the waiting room highlighting the 
epidemiology, risks, and symptoms of AMD
 Creation of an informative flyer for each 
examination room highlighting the 
epidemiology, risks, and symptoms of AMD
 Primary Care Provider
 Assess provider knowledge of AMD risk 
factors, early signs and symptoms, and 
care management using a 10 point 
questionnaire
 SurveyMonkey distributed to CFM 
providers and three regional primary care 
practices
 Assess provider comfort with fundus 
examination and Amsler grid testing
 Formation of an informative flyer for each 
examination room highlighting the 
epidemiology, risks, and symptoms of 
AMD, and care management steps
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In a 2009 prospective longitudinal study, 98% of 2nd year medical students reported self-rated 
competency in optic disc visualization.  However, expert audits of 3rd and 4th year student 
charts demonstrated that 43% of post-family medicine and 91% of post-internal medicine 
workups reflected inadequate eye evaluations.  The authors concluded that skills performance 
decayed when not habitually practiced.14 These results can almost certainly be extrapolated 
to primary care residency training and beyond.  
Results – patient (n=46) 6a
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Evaluation of effectiveness and 
limitations
 Only 18% of patients reported adequate or 
expert knowledge of early signs and 
symptoms.  50% reported poor to no 
knowledge.
 Similarly, 18% of patients reported adequate 
knowledge of risk factors.  50% reported poor 
to no knowledge.
 64% of patients did not know what AMD was, 
but 74% wish they knew more about the 
disease.  
 Patients with AMD in one or both eyes, or who 
have family members with AMD, were more 
likely to be knowledgeable of signs, 
symptoms and risk factors.
 This data suggests that knowledge of AMD risk 
factors, signs and symptoms are lacking in the 
general adult population.  However, the vast 
majority desire to know more
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 The findings suggest a need and desire for 
timely education and risk identification by 
primary care providers
 Although not directly shown by our data, it is 
reasonable to infer that patients lack 
adequate knowledge of the disease until 
they are diagnosed with AMD.  An 
association may be revealed if the survey 
were extended to capture more patients with 
and without the diagnosis
 Organization and order of survey questions 
may have inadvertently tipped patients and 
altered responses with respect to knowledge 
level
 We propose to evaluate the effectiveness of 
interventions by readministering questionnaire 
to same patients after they have reviewed 
the handout
Evaluation of effectiveness and 
limitations
 70% of providers routinely ask about visits at 
Well-visits.  However, 43% of providers 
somewhat or completely disagree that they 
can comfortably perform a fundus exam 
 52% of providers somewhat or completely 
disagree that they can comfortably perform 
and interpret the Amsler grid test 
 Approximately 40% of providers wish they 
knew more about the risk factors for AMD, 
while only 34% considered themselves to have 
adequate or expert knowledge of the risk 
factors 
 43% of providers wish they knew more of early 
signs and symptoms of AMD, while 53% 
considered themselves adequate or expert 
 39% of providers had poor to no knowledge of 
the available low-vision rehab services, and 
43% had poor to no knowledge of the 
available low-vision community support 
resources
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 While 70% of providers report routinely asking 
about vision during well-visits, depth of 
questioning and line of questioning looking 
specifically for AMD is unclear
 The PCP survey was announced and residents 
and faculty were asked to participate during 
a clinic team huddle.  While clearly stated 
that responses were confidential and used for 
internal analysis only, a significant Hawthorne 
effect/observation bias may exist
 We propose to evaluate the effectiveness of 
interventions by readministering questionnaires 
after review of PCP care management 
handout. 
 Further evaluate with formal assessment 
of interviewing and physical exam skills, 
and professional chart audits
Recommendations for future 
interventions and projects
For at-risk patients, PCPs play a crucial role in recognizing functional and 
anatomic symptoms, issuing timely referrals, and overseeing risk factor 
modification.  In patients with uncorrectable vision loss, the PCP’s role shifts 
to optimizing quality of life and facilitating low-vision rehabilitation.15
 Creation of an automated page in the EMR for the guidance of 
primary care provider screening questions
 It is not uncommon for people with even severe monocular vision loss 
to be unaware of their condition if they have good vision in the fellow 
eye - simply asking “Any changes in vision?” may not be enough.  Ask 
all adult smokers and/or those with a family history specific vision 
questions (Table 1)
 Educate all adult smokers and/or those with a family history of AMD 
about the early signs and symptoms of AMD
 Larger trials could provide more insight into patient and provider 
knowledge of AMD that encompasses a more diverse population
 We recommend formal workshops that encompass funduscopic 
examination, referral guidelines, treatment options, and follow-up for 
AMD to all primary care providers using a reiterative training model
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Table 1.15
How did you see 10 years ago?
How is your reading?
What can’t you do now that you 
were previously able to?
Have you noticed that straight lines 
have become distorted or wavy?
Have you noticed any dark areas, 
blurry areas, or whiteout?
When did you first notice changes in 
your vision?
How has your vision changed in the 
last 3 months?
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